Quarry LP Invests $4.48 Million in Catalent, Inc. (NYSE:CTLT)

Quarry LP bought a new stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 74,000 shares of the company's stock, valued at approximately $4,482,000. Catalent accounts for approximately 1.1% of Quarry LP's investment portfolio, making the stock its 8th biggest position.

Several other institutional investors also recently bought and sold shares of CTLT. Brooklyn Investment Group purchased a new position in shares of Catalent in the 3rd quarter worth approximately $31,000. Sentry Investment Management LLC purchased a new position in Catalent during the third quarter worth $53,000. Longfellow Investment Management Co. LLC increased its position in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after acquiring an additional 305 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after acquiring an additional 212 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. raised its stake in shares of Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company's stock valued at $72,000 after acquiring an additional 431 shares during the period.

Catalent Price Performance

CTLT traded up $0.17 during trading on Thursday, hitting $62.01. 1,864,329 shares of the stock were exchanged, compared to its average volume of 2,039,502. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $62.20. The firm has a 50 day simple moving average of $60.00 and a 200 day simple moving average of $58.62. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the previous year, the business earned ($0.10) earnings per share. The business's quarterly revenue was up 4.2% compared to the same quarter last year. On average, analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CTLT. William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Robert W. Baird reissued a "neutral" rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Finally, StockNews.com raised Catalent from a "sell" rating to a "hold" rating in a research report on Monday. Eight analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.